ערך בספרים למניה: revbiosciences.com (REVB)

Revelation Biosciences currently lacks consistent profits, as its stability depends on clinical trial outcomes. The BVPS metric visualizes this process, where the value 18.04 serves as the baseline indicator of current value. The solution will be the commercialization of products to grow margins, while the foundation will be the Gemini ecosystem, which unites scientific institutes around proprietary molecules.

For the biopharmaceutical business of Revelation Biosciences (REVB), which is developing the Gemini platform to combat sepsis, BVPS dynamics serve as an indicator of the company's material base preservation. This metric is calculated as the difference between all assets and liabilities divided by the number of shares, allowing an investor to assess the real value of ownership and the enterprise's level of capital protection in the absence of operating profit.